Who owns OmniAb, Inc. (OA)? Elite investor 13F holders
4 tracked elite investors reported holding OmniAb, Inc as of 2026-06-30, including Renaissance Technologies LLC, D.E. Shaw, Anson Funds, Saba Capital. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
4 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | OMNIAB INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 1476861.00 USD | 600350.000000 | Shares | add | Original filing |
| D.E. Shaw | OMNIAB INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 1376134.00 USD | 559404.000000 | Shares | add | Original filing |
| Anson Funds | OmniAb Inc | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 29109.00 USD | 11833.000000 | Shares | — | Original filing |
| Saba Capital | OmniAb Inc | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 1418.00 USD | 18000.000000 | Shares | reduce | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.